Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer

Defining normoxia, physoxia and hypoxia in tumours—implications for treatment response

(2014) S R McKeown   BRITISH JOURNAL OF RADIOLOGY

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

(2013) R Alvarez et al.   BRITISH JOURNAL OF CANCER

Microenvironment and tumor cell plasticity: An easy way out

(2013) Maria Letizia Taddei et al.   CANCER LETTERS

Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer

(2013) N. Awasthi et al.   CARCINOGENESIS

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumour Hypoxia Affects the Responsiveness of Cancer Cells to Chemotherapy and Promotes Cancer Progression

(2012) Jean-Philippe Cosse et al.   Anti-Cancer Agents in Medicinal Chemistry

TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules

(2012) Qian Liu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Translational Therapeutic Opportunities in Ductal Adenocarcinoma of the Pancreas

(2012) M. Hidalgo et al.   CLINICAL CANCER RESEARCH

Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys

(2011) Donald Jung et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer

(2011) J. D. Sun et al.   CLINICAL CANCER RESEARCH

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies

(2011) G. J. Weiss et al.   CLINICAL CANCER RESEARCH

Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

(2011) Daniel D. Von Hoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Pathophysiological Response to Hypoxia — From the Molecular Mechanisms of Malady to Drug Discovery: Epigenetic Regulation of the Hypoxic Response via Hypoxia-Inducible Factor and Histone Modifying Enzymes

(2011) Imari Mimura et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302

(2011) F. Meng et al.   MOLECULAR CANCER THERAPEUTICS

Toxicological Study and Efficacy of Blank and Paclitaxel-Loaded Lipid Nanocapsules After i.v. Administration in Mice

(2010) José Hureaux et al.   PHARMACEUTICAL RESEARCH

Potent and Highly Selective Hypoxia-Activated Achiral Phosphoramidate Mustards as Anticancer Drugs

(2008) Jian-Xin Duan et al.   JOURNAL OF MEDICINAL CHEMISTRY